Organobalance Gmbh

Basf Se Corporation

Novozymes A/s

Basf Aktiengesellschaft

Lubrizol Advanced Materials, Inc.

Alzchem Ag

Greenforce Nutrition Gmbh

Markus Veen

Christine Lang

Mewes Boettner

Eckhard Budde

Martin Ryser

Bruno Kaesler

Andreas Reindl

Rolf Knöll

Mewes Böttner

Andreas Raab

Andreas Künkel

Michael Schilling

Budde Eckhard

Andreas Heilmann

Andreas Hellmann

Rolf Knoll

Achim Budemann

Rolf Knoell

Barbara Nieß

The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: Another aspect of the present invention is an analog or fragment of said microorganism which is thermally inactivated or lyophilized, wherein said analog or fragment retains the capability of specifically binding to. In addition, the present invention encompasses compositions and additives for food, feed or drinks comprising the microorganism belonging to the group of lactic acid bacteria which specifically bind toor an analog or fragment thereof. Moreover, uses of said microorganism or said analog or fragment thereof for the preparation of an anticariogenic or pharmaceutical composition or anticariogenic food or feedstuff as well as methods for producing said compositions or food or feedstuff are provided by the present invention.

Means and methods for preventing and/or treating caries

Described are microorganisms which are, in a first aspect, able to to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit the growth of microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the resident skin micro flora. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Methods and means for protecting the skin against pathogenic microorganisms

The present invention relates to a method for preparing 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof by culturing organisms, in particular yeasts. Furthermore, the invention relates to the preparation of the nucleic acid constructs required for preparing the genetically modified organisms and to said genetically modified organisms, in particular yeasts, themselves.

Preparation of 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof in transgenic organisms

The invention relates to an isolated genetically modified microorganism in which the gene IDH1 and at least one of the genes SDH2 and DIC1 are under the control of a first promoter that is repressed to a growth culture medium by means of a cultivation additive and is active in the absence of the cultivation additive. The genes that are part of the group comprising 'PYC1, ACS1, CIT1, ACO1, ICL1, MSL1, and CIT2, optionally also MDH3' are constitutively active. The invention further relates to uses of such a microorganism, especially for producing succinic acid.

Microorganism for the production of succinic acid

Described is a microorganism belonging to the group of lactic acid bacteria which is able to drastically reduce the peptide concentration in saliva thereby depleting the substrate used by anaerobic microorganisms of the oral micro-flora which are the causative agent for oral malodour. Moreover, described is a microorganism belonging to the group of lactic acid bacteria which is able to stimulate the growth ofbut does not stimulate the growth ofand/or. Also described are compositions containing the above-mentioned microorganisms, their use for preventing and/or treating oral malodour and/or halitosis and to methods for preventing and/or treating oral malodour and/or halitosis.

Use and methods for preventing and/or treating oral malodour

The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism withwhich has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism andand (d) detecting aggregates by the occurrence of a pellet. Another aspect of the present invention is an analog or fragment of said microorganism which is thermally inactivated or lyophilized, wherein said analog or fragment retains the capability of specifically binding to. In addition, the present invention encompasses compositions and additives for food, feed or drinks comprising the microorganism belonging to the group of lactic acid bacteria which specifically bind toor an analog or fragment thereof. Moreover, uses of said microorganism or said analog or fragment thereof for the preparation of an anticariogenic or pharmaceutical composition or anticariogenic food or feedstuff as well as methods for producing said compositions or food or feedstuff are provided by the present invention.

[object Object]

The invention concerns new isolatedcells, which are capable to aggregateunder culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.

Method for the production of 7-dehydrocholesterol and/or the biosynthetic intermediate or subsequent products thereof in transgenic organisms

The present invention relates to a method for the production of ergosta-5,7-dienol and/or its biosynthetic intermediates and/or metabolites by culturing genetically modified organisms, and to the genetically modified organisms, in particular yeasts, themselves.

Method for producing ergosta-5,7-dienol and/or biosynthetic intermediate and/or secondary products thereof in transgenic organisms

Growing community of inventors

Berlin, Germany

Markus Veen